Hotaka Shinzato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hotaka Shinzato has a total of 338 co-authors. Here are the top co-authors by number of shared publications:
- Go Okada
Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
6 shared publications - Kazuhiro Kurihara
Department of Neuropsychiatry, Graduate School of Medicine University of the Ryukyus Okinawa Japan
6 shared publications Munenaga Koda
Graduate School of Technology, Industrial and Social Sciences Tokushima University Tokushima Japan
6 shared publicationsTsuyoshi Kondo
Department of Neuropsychiatry, Graduate School of Medicine University of the Ryukyus Okinawa Japan
6 shared publications- Tsuyoshi Kondo
Department of Neuropsychiatry, Graduate School of Medicine University of the Ryukyus Okinawa Japan
6 shared publications - Yoshikazu Takaesu
Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan
6 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Decomposing neuroanatomical heterogeneity in depression: insights from an ENIGMA major depressive disorder working group study in 5146 individuals
The clinical and biological heterogeneity of major depressive disorder (MDD) may reflect the aggregation of different conditions with distinct pathologies under a single diagnostic label. Neuroanatomical heterogeneity in MDD was examined using a harmonized, age- and sex-matched sample from the ENIGMA MDD consortium (N = 5146; age range: 9–82 years; 64% female). Analyses of global neurostrucutral variability revealed greater cortical thickness heterogeneity in MDD compared with healthy controls (Cohen’s d = –0.26). Regionally, increased variability in cortical thickness was most prominent in the cingulate (+6.1 to +6.6% more variation in MDD) and insular (+5.8%) cortices, as well as in the frontal (+5.7 to +6.8%) and temporal (+6.1 to +6.8%) lobes. Heterogeneity in cortical thickness was more pronounced among patients using antidepressant medication (Cohen’s d = –0.39). Patient-specific analyses further showed that individuals with markedly increased cortical thickness variability (th percentile relative to the normative range) exhibited greater depressive symptom severity than those within the normative range (5 th –95 th percentile; Cohen’s d = 0.19–0.36). Overall, the results indicate that neuroanatomical heterogeneity in MDD is primarily expressed in cortical thickness, offering refined insights into the neurobiological complexity of structural alterations associated with depression. These findings could guide future stratification efforts examining whether regionally confined changes in cortical thickness within areas of pronounced variability reflect clinically meaningful patient subgroups.
- 23 June 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessDecomposing neuroanatomical heterogeneity in depression: insights from an ENIGMA major depressive disorder working group study in 5146 individuals
The clinical and biological heterogeneity of major depressive disorder (MDD) may reflect the aggregation of different conditions with distinct pathologies under a single diagnostic label. Neuroanatomical heterogeneity in MDD was examined using a harmonized, age- and sex-matched sample from the ENIGMA MDD consortium (N = 5146; age range: 9–82 years; 64% female). Analyses of global neurostrucutral variability revealed greater cortical thickness heterogeneity in MDD compared with healthy controls (Cohen’s d = –0.26). Regionally, increased variability in cortical thickness was most prominent in the cingulate (+6.1 to +6.6% more variation in MDD) and insular (+5.8%) cortices, as well as in the frontal (+5.7 to +6.8%) and temporal (+6.1 to +6.8%) lobes. Heterogeneity in cortical thickness was more pronounced among patients using antidepressant medication (Cohen’s d = –0.39). Patient-specific analyses further showed that individuals with markedly increased cortical thickness variability (th percentile relative to the normative range) exhibited greater depressive symptom severity than those within the normative range (5 th –95 th percentile; Cohen’s d = 0.19–0.36). Overall, the results indicate that neuroanatomical heterogeneity in MDD is primarily expressed in cortical thickness, offering refined insights into the neurobiological complexity of structural alterations associated with depression. These findings could guide future stratification efforts examining whether regionally confined changes in cortical thickness within areas of pronounced variability reflect clinically meaningful patient subgroups.
- 15 June 2026
- Published by Springer Nature in Nature Mental Health
- Vol. 4 (7) , 1175-1186
Vertex-wise cortical abnormalities in major depressive disorder from 64 cohorts from the DIRECT and ENIGMA MDD consortia
- 15 June 2026
- Published by Springer Nature in Nature Mental Health
- Vol. 4 (7) , 1175-1186
Vertex-wise cortical abnormalities in major depressive disorder from 64 cohorts from the DIRECT and ENIGMA MDD consortia
- Open Access
- 3 November 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (12) , 5625-5636
Regional brain morphology and current antidepressant use: findings from 32 international cohorts from the ENIGMA major depressive disorder working group
The understanding of how antidepressant (AD) use is associated with brain structure in individuals with major depressive disorder (MDD) remains incomplete. We aimed to examine the association between AD medication use and brain morphology in relation to age and sex by pooling structural neuroimaging and clinical data from 32 cohorts within the ENIGMA-MDD working group. Interaction effects of group (2076 cases with current AD use (AD), 1495 cases not currently taking AD (nAD) and 5125 healthy controls (HC)) with age and sex, and main effects of group on regional brain structure (cortical surface area and thickness, and subcortical volume) were examined. Additionally, we examined the effect of AD type (SSRI, SNRI or mirtazapine) and duration of use on brain morphology. Younger individuals in the AD group showed lower bilateral middle temporal gyrus thickness compared to nAD and HC, but this was not seen in older individuals (crossover around 50 years). Lower hippocampal volume and thinner inferior temporal gyrus were shown in AD compared to nAD. These effects were independent of group differences in disease-course-related measures, but were driven by depressive symptom severity. Greater bilateral rostral anterior cingulate thickness was found in individuals older than approximately 40 years taking mirtazapine compared to individuals taking SSRIs or SNRIs. Evidence for subtle structural brain differences in temporal and limbic regions in individuals with MDD who currently use AD medication were found compared to those not currently taking AD medication. Future longitudinal studies are needed to determine the causality of these associations.
- 3 November 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (12) , 5625-5636
Open AccessRegional brain morphology and current antidepressant use: findings from 32 international cohorts from the ENIGMA major depressive disorder working group
The understanding of how antidepressant (AD) use is associated with brain structure in individuals with major depressive disorder (MDD) remains incomplete. We aimed to examine the association between AD medication use and brain morphology in relation to age and sex by pooling structural neuroimaging and clinical data from 32 cohorts within the ENIGMA-MDD working group. Interaction effects of group (2076 cases with current AD use (AD), 1495 cases not currently taking AD (nAD) and 5125 healthy controls (HC)) with age and sex, and main effects of group on regional brain structure (cortical surface area and thickness, and subcortical volume) were examined. Additionally, we examined the effect of AD type (SSRI, SNRI or mirtazapine) and duration of use on brain morphology. Younger individuals in the AD group showed lower bilateral middle temporal gyrus thickness compared to nAD and HC, but this was not seen in older individuals (crossover around 50 years). Lower hippocampal volume and thinner inferior temporal gyrus were shown in AD compared to nAD. These effects were independent of group differences in disease-course-related measures, but were driven by depressive symptom severity. Greater bilateral rostral anterior cingulate thickness was found in individuals older than approximately 40 years taking mirtazapine compared to individuals taking SSRIs or SNRIs. Evidence for subtle structural brain differences in temporal and limbic regions in individuals with MDD who currently use AD medication were found compared to those not currently taking AD medication. Future longitudinal studies are needed to determine the causality of these associations.
- Open Access
- 20 August 2024
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 78 (10) , 563-579
The status of MRI databases across the world focused on psychiatric and neurological disorders
Neuroimaging databases for neuro‐psychiatric disorders enable researchers to implement data‐driven research approaches by providing access to rich data that can be used to study disease, build and validate machine learning models, and even redefine disease spectra. The importance of sharing large, multi‐center, multi‐disorder databases has gradually been recognized in order to truly translate brain imaging knowledge into real‐world clinical practice. Here, we review MRI databases that share data globally to serve multiple psychiatric or neurological disorders. We found 42 datasets consisting of 23,293 samples from patients with psychiatry and neurological disorders and healthy controls; 1245 samples from mood disorders (major depressive disorder and bipolar disorder), 2015 samples from developmental disorders (autism spectrum disorder, attention‐deficit hyperactivity disorder), 675 samples from schizophrenia, 1194 samples from Parkinson's disease, 5865 samples from dementia (including Alzheimer's disease), We recognize that large, multi‐center databases should include governance processes that allow data to be shared across national boundaries. Addressing technical and regulatory issues of existing databases can lead to better design and implementation and improve data access for the research community. The current trend toward the development of shareable MRI databases will contribute to a better understanding of the pathophysiology, diagnosis and assessment, and development of early interventions for neuropsychiatric disorders.
- 20 August 2024
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 78 (10) , 563-579
Open AccessThe status of MRI databases across the world focused on psychiatric and neurological disorders
Neuroimaging databases for neuro‐psychiatric disorders enable researchers to implement data‐driven research approaches by providing access to rich data that can be used to study disease, build and validate machine learning models, and even redefine disease spectra. The importance of sharing large, multi‐center, multi‐disorder databases has gradually been recognized in order to truly translate brain imaging knowledge into real‐world clinical practice. Here, we review MRI databases that share data globally to serve multiple psychiatric or neurological disorders. We found 42 datasets consisting of 23,293 samples from patients with psychiatry and neurological disorders and healthy controls; 1245 samples from mood disorders (major depressive disorder and bipolar disorder), 2015 samples from developmental disorders (autism spectrum disorder, attention‐deficit hyperactivity disorder), 675 samples from schizophrenia, 1194 samples from Parkinson's disease, 5865 samples from dementia (including Alzheimer's disease), We recognize that large, multi‐center databases should include governance processes that allow data to be shared across national boundaries. Addressing technical and regulatory issues of existing databases can lead to better design and implementation and improve data access for the research community. The current trend toward the development of shareable MRI databases will contribute to a better understanding of the pathophysiology, diagnosis and assessment, and development of early interventions for neuropsychiatric disorders.
- Open Access
- 27 June 2024
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (3) , 585-590
Successful treatment with guanfacine in a long‐COVID case manifesting marked cognitive impairment
Background: Persistent cognitive impairment is a serious consequence of the post‐COVID condition. However, there have been no established effective treatments for this pathophysiology supported by sufficient evidence.Case Presentation: A 32‐year‐old woman became aware of difficulty in word recalling, reading, and writing as well as difficulty in completing various household multitasks 3 weeks after the COVID‐19 infection. Although blood tests, magnetic resonance imaging, electroencephalography, and Kohs block design test were all within normal limits, completion time by trail making test (TMT) A or B was markedly delayed. Finally, she was referred to our hospital 3 months after the infection. At baseline, the THINC integrated tool (THINC‐it), a digital battery consisting of the five‐item version of the perceived deficit questionnaire (PDQ‐5), choice reaction time (CRT), 1‐back test, digit symbol substitution test (DSST), and TMT‐B, revealed poor capability in attention, working memory, and executive function. Also, near‐infrared spectroscopy (NIRS) demonstrated no activation in frontal or temporal regions during verbal fluency task. Extended‐release guanfacine (GXR) 2 mg/day was initiated and a month later was elevated up to 4 mg/day as a maintenance dose. The PDQ‐5, CRT, 1‐back test, DSST, and TMT‐B were dramatically improved 1 month after GXR treatment. NIRS finding was also normalized after 2 months of treatment. These effects were successfully maintained throughout the 6‐month follow‐up period.Conclusion: GXR may be helpful in improving subjective/objective cognitive functioning and frontotemporal brain activity in long‐COVID patients manifesting apparent cognitive impairment.
- 27 June 2024
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (3) , 585-590
Open AccessSuccessful treatment with guanfacine in a long‐COVID case manifesting marked cognitive impairment
Background: Persistent cognitive impairment is a serious consequence of the post‐COVID condition. However, there have been no established effective treatments for this pathophysiology supported by sufficient evidence.Case Presentation: A 32‐year‐old woman became aware of difficulty in word recalling, reading, and writing as well as difficulty in completing various household multitasks 3 weeks after the COVID‐19 infection. Although blood tests, magnetic resonance imaging, electroencephalography, and Kohs block design test were all within normal limits, completion time by trail making test (TMT) A or B was markedly delayed. Finally, she was referred to our hospital 3 months after the infection. At baseline, the THINC integrated tool (THINC‐it), a digital battery consisting of the five‐item version of the perceived deficit questionnaire (PDQ‐5), choice reaction time (CRT), 1‐back test, digit symbol substitution test (DSST), and TMT‐B, revealed poor capability in attention, working memory, and executive function. Also, near‐infrared spectroscopy (NIRS) demonstrated no activation in frontal or temporal regions during verbal fluency task. Extended‐release guanfacine (GXR) 2 mg/day was initiated and a month later was elevated up to 4 mg/day as a maintenance dose. The PDQ‐5, CRT, 1‐back test, DSST, and TMT‐B were dramatically improved 1 month after GXR treatment. NIRS finding was also normalized after 2 months of treatment. These effects were successfully maintained throughout the 6‐month follow‐up period.Conclusion: GXR may be helpful in improving subjective/objective cognitive functioning and frontotemporal brain activity in long‐COVID patients manifesting apparent cognitive impairment.
- Open Access
- 21 May 2024
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (3) , 512-520
Cluster analysis of patients with alcohol use disorder featuring alexithymia, depression, and diverse drinking behavior
Aim: This study aimed to identify subgroups of alcohol use disorder (AUD) based on a multidimensional combination of alexithymia, depression, and diverse drinking behavior.Method: We recruited 176 patients with AUD, which were initially divided into non‐alexithymic (n = 130) and alexithymic (n = 46) groups using a cutoff score of 61 on the Toronto Alexithymia Scale (TAS‐20). Subsequently, the profiles of the two groups were compared. Thereafter, a two‐stage cluster analysis using hierarchical and K‐means methods was performed with the Z‐scores from the TAS‐20, the Quick Inventory of Depressive Symptomatology Self‐Report Japanese Version, the 12‐item questionnaire for quantitative assessment of depressive mixed state, and the 20‐item questionnaire for drinking behavior pattern.Results: In the first analysis, Alexithymic patients with AUD showed greater depressive symptoms and more pathological drinking behavior patterns than those without alexithymia. Cluster analysis featuring alexithymia, depression, and drinking behavior identified three subtypes: Cluster 1 (core AUD type) manifesting pathological drinking behavior highlighting automaticity; Cluster 2 (late‐onset type) showing relatively late‐onset alcohol use and fewer depressive symptoms or pathological drinking behavior; and Cluster 3 (alexithymic type) characterized by alexithymia, depression, and pathological drinking behavior featuring greater coping with negative affect.Conclusion: The multidimensional model with alexithymia, depression, and diverse drinking behavior provided possible practical classification of AUD. The alexithymic subtype may require more caution, and additional support for negative affect may be necessary due to accompanying mood problems and various maladaptive drinking behaviors.
- 21 May 2024
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (3) , 512-520
Open AccessCluster analysis of patients with alcohol use disorder featuring alexithymia, depression, and diverse drinking behavior
Aim: This study aimed to identify subgroups of alcohol use disorder (AUD) based on a multidimensional combination of alexithymia, depression, and diverse drinking behavior.Method: We recruited 176 patients with AUD, which were initially divided into non‐alexithymic (n = 130) and alexithymic (n = 46) groups using a cutoff score of 61 on the Toronto Alexithymia Scale (TAS‐20). Subsequently, the profiles of the two groups were compared. Thereafter, a two‐stage cluster analysis using hierarchical and K‐means methods was performed with the Z‐scores from the TAS‐20, the Quick Inventory of Depressive Symptomatology Self‐Report Japanese Version, the 12‐item questionnaire for quantitative assessment of depressive mixed state, and the 20‐item questionnaire for drinking behavior pattern.Results: In the first analysis, Alexithymic patients with AUD showed greater depressive symptoms and more pathological drinking behavior patterns than those without alexithymia. Cluster analysis featuring alexithymia, depression, and drinking behavior identified three subtypes: Cluster 1 (core AUD type) manifesting pathological drinking behavior highlighting automaticity; Cluster 2 (late‐onset type) showing relatively late‐onset alcohol use and fewer depressive symptoms or pathological drinking behavior; and Cluster 3 (alexithymic type) characterized by alexithymia, depression, and pathological drinking behavior featuring greater coping with negative affect.Conclusion: The multidimensional model with alexithymia, depression, and diverse drinking behavior provided possible practical classification of AUD. The alexithymic subtype may require more caution, and additional support for negative affect may be necessary due to accompanying mood problems and various maladaptive drinking behaviors.
- Open Access
- 11 March 2024
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (2) , 381-388
Drinking behavior patterns may be associated with persistent depressive symptoms after alcohol abstinence in alcohol use disorder
Aim: This study examined the association between drinking behavior patterns and depressive symptoms after alcohol abstinence in patients with alcohol use disorder (AUD).Method: We recruited 102 AUD inpatients with baseline depressive symptoms, indicated by scores ≥6 on the Quick Inventory of Depressive Symptomatology Self‐Report Japanese Version (QIDS‐SR‐J) pre‐detoxification. Post‐4‐week abstinence, remission was defined as QIDS‐SR‐J scores n = 51) and persistent (n = 51) groups. Comparative analyses were conducted using patient profiles and the Drinking Behavior Pattern 20‐item Questionnaire (DBP‐20). Logistic regression identified factors related to post‐abstinence persistent depression. Receiver operating characteristic curve analysis determined DBP‐20 cutoff scores differentiating between persistent and remitted depression.Results: The persistent group exhibited higher scores in the DBP‐20 “coping with negative affect” subscale. Logistic regression showed low education, unemployment, and using alcohol for coping as significant factors for persistent depression. Conversely, an automatic drinking pattern indicated natural remission post‐abstinence. A subscale score of ≥8 in alcohol use for coping, especially among unemployed patients, predicted persistent depression (sensitivity 86.8%, positive predictive value 73.3%).Conclusion: Unemployed patients with AUD using alcohol to cope with negative affect may experience residual depression even after detoxification. In contrast, patients with AUD with predominantly automatic drinking behavior may exhibit natural remission post‐abstinence.
- 11 March 2024
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (2) , 381-388
Open AccessDrinking behavior patterns may be associated with persistent depressive symptoms after alcohol abstinence in alcohol use disorder
Aim: This study examined the association between drinking behavior patterns and depressive symptoms after alcohol abstinence in patients with alcohol use disorder (AUD).Method: We recruited 102 AUD inpatients with baseline depressive symptoms, indicated by scores ≥6 on the Quick Inventory of Depressive Symptomatology Self‐Report Japanese Version (QIDS‐SR‐J) pre‐detoxification. Post‐4‐week abstinence, remission was defined as QIDS‐SR‐J scores n = 51) and persistent (n = 51) groups. Comparative analyses were conducted using patient profiles and the Drinking Behavior Pattern 20‐item Questionnaire (DBP‐20). Logistic regression identified factors related to post‐abstinence persistent depression. Receiver operating characteristic curve analysis determined DBP‐20 cutoff scores differentiating between persistent and remitted depression.Results: The persistent group exhibited higher scores in the DBP‐20 “coping with negative affect” subscale. Logistic regression showed low education, unemployment, and using alcohol for coping as significant factors for persistent depression. Conversely, an automatic drinking pattern indicated natural remission post‐abstinence. A subscale score of ≥8 in alcohol use for coping, especially among unemployed patients, predicted persistent depression (sensitivity 86.8%, positive predictive value 73.3%).Conclusion: Unemployed patients with AUD using alcohol to cope with negative affect may experience residual depression even after detoxification. In contrast, patients with AUD with predominantly automatic drinking behavior may exhibit natural remission post‐abstinence.
- Open Access
- 9 December 2023
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 43 (4) , 633-640
Associations between relapse and drinking behaviors in patients with alcohol use disorders: A 6‐month prospective study
Background: Habitual behaviors, rather than goal‐oriented behaviors, mainly characterize drinking patterns in patients with alcohol use disorder (AUD). However, few studies have focused on the influence of drinking behavior on AUD relapse. This prospective study examined associations between drinking behavior patterns and alcohol‐use relapse using the 20‐item questionnaire for drinking behavior patterns (DBP‐20).Methods: We enrolled patients with AUD and compared the cohort's demographic data and 6‐month outcomes based on the DBP‐20 and the Alcohol Use Disorders Identification Test between two groups (alcohol use relapse vs. abstinence). We also assessed the results for significant factors related to relapse.Results: We included 105 patients with AUD. More patients in the relapse group (n = 63) were active smokers and lived alone, while fewer took medication with cyanamide or disulfiram than those in the abstinence group (n = 42). The DBP‐20 automaticity subscale score was higher in the relapse group than that in the abstinence group. Current smoker, living alone, and automatic drinking habits were significantly associated with AUD relapse.Conclusions: Automaticity may be a risky drinking behavior that leads to future relapse in patients with AUD, justifying behavioral strategies to combat automatic drinking for relapse prevention.
- 9 December 2023
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 43 (4) , 633-640
Open AccessAssociations between relapse and drinking behaviors in patients with alcohol use disorders: A 6‐month prospective study
Background: Habitual behaviors, rather than goal‐oriented behaviors, mainly characterize drinking patterns in patients with alcohol use disorder (AUD). However, few studies have focused on the influence of drinking behavior on AUD relapse. This prospective study examined associations between drinking behavior patterns and alcohol‐use relapse using the 20‐item questionnaire for drinking behavior patterns (DBP‐20).Methods: We enrolled patients with AUD and compared the cohort's demographic data and 6‐month outcomes based on the DBP‐20 and the Alcohol Use Disorders Identification Test between two groups (alcohol use relapse vs. abstinence). We also assessed the results for significant factors related to relapse.Results: We included 105 patients with AUD. More patients in the relapse group (n = 63) were active smokers and lived alone, while fewer took medication with cyanamide or disulfiram than those in the abstinence group (n = 42). The DBP‐20 automaticity subscale score was higher in the relapse group than that in the abstinence group. Current smoker, living alone, and automatic drinking habits were significantly associated with AUD relapse.Conclusions: Automaticity may be a risky drinking behavior that leads to future relapse in patients with AUD, justifying behavioral strategies to combat automatic drinking for relapse prevention.
- Open Access
- 25 November 2023
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 20 (11) , 1027-1033
Elevated Brain-Derived Neurotrophic Factor Levels During Depressive Mixed States
Objective Neurotrophin-like brain-derived neurotrophic factor (BDNF) and pro-inflammatory cytokines may modulate the pathophysiology of mood disorders. Although several studies show alterations in these biomarkers during the depressive, manic, and euthymic states of mood disorders, evidence is lacking for those in a mixed state. Therefore, this study aimed to investigate the relationship between the depressive mixed state (DMX) and peripheral neurobiological factors.Methods We enrolled 136 patients with major depressive episodes. Depressive symptoms were assessed using the Quick Inventory of Depressive Symptomatology Self-Report Japanese version (QIDS-SR-J). The severity of DMX was assessed using the self-administered 12-item questionnaire (DMX-12). Categorical screening as DMX-positive (n=54) was determined by a cutoff score of 13 or more in the specific eight symptoms from the DMX-12; the remaining were DMX-negative (n=82). Serum BDNF, tumor necrosis factor-α, highsensitivity C-reactive protein, and interleukin-6 levels were measured.Results When comparing biomarkers between the DMX-positive and DMX-negative groups, higher serum BDNF concentration in the DMX-positive group than in the DMX-negative group was the only significant finding (p=0.009). A positive correlation existed between the total score of the eight specific symptoms of DMX-12 and the BDNF concentration (r=0.190, p=0.027). After adjustment for confounders, logistic regression analysis revealed that BDNF (odds ratio [OR]=1.07, 95% confidence interval [CI]=1.00–1.14, p=0.045), bipolar diagnosis (OR=3.43, 95% CI=1.36–8.66, p=0.009), and total QIDS-SR-J score (OR=1.29, 95% CI=1.15–1.43, p<0.001) were significantly associated with DMX positivity.Conclusion BDNF was positively associated with DMX severity, suggesting that higher BDNF concentrations may be involved in the pathophysiology of DMX.
- 25 November 2023
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 20 (11) , 1027-1033
Open AccessElevated Brain-Derived Neurotrophic Factor Levels During Depressive Mixed States
Objective Neurotrophin-like brain-derived neurotrophic factor (BDNF) and pro-inflammatory cytokines may modulate the pathophysiology of mood disorders. Although several studies show alterations in these biomarkers during the depressive, manic, and euthymic states of mood disorders, evidence is lacking for those in a mixed state. Therefore, this study aimed to investigate the relationship between the depressive mixed state (DMX) and peripheral neurobiological factors.Methods We enrolled 136 patients with major depressive episodes. Depressive symptoms were assessed using the Quick Inventory of Depressive Symptomatology Self-Report Japanese version (QIDS-SR-J). The severity of DMX was assessed using the self-administered 12-item questionnaire (DMX-12). Categorical screening as DMX-positive (n=54) was determined by a cutoff score of 13 or more in the specific eight symptoms from the DMX-12; the remaining were DMX-negative (n=82). Serum BDNF, tumor necrosis factor-α, highsensitivity C-reactive protein, and interleukin-6 levels were measured.Results When comparing biomarkers between the DMX-positive and DMX-negative groups, higher serum BDNF concentration in the DMX-positive group than in the DMX-negative group was the only significant finding (p=0.009). A positive correlation existed between the total score of the eight specific symptoms of DMX-12 and the BDNF concentration (r=0.190, p=0.027). After adjustment for confounders, logistic regression analysis revealed that BDNF (odds ratio [OR]=1.07, 95% confidence interval [CI]=1.00–1.14, p=0.045), bipolar diagnosis (OR=3.43, 95% CI=1.36–8.66, p=0.009), and total QIDS-SR-J score (OR=1.29, 95% CI=1.15–1.43, p<0.001) were significantly associated with DMX positivity.Conclusion BDNF was positively associated with DMX severity, suggesting that higher BDNF concentrations may be involved in the pathophysiology of DMX.
- Open Access
- 5 November 2023
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 43 (4) , 587-595
Age‐related cognitive decline is accelerated in alcohol use disorder
This study aimed to examine potential cognitive impairments in patients with alcohol use disorder (AUD), and explore the factors affecting them. We recruited 97 inpatients with AUD, showing superficially normal cognitive function (mini‐mental state examination score ≥24) for this study. We assessed cognitive function after a 4‐week post‐abstinence period using the Brief Assessment of Cognition in Schizophrenia‐Japanese version (BACS‐J). Relationships between BACS‐J subcategory/composite raw scores and Z‐scores (deviation from standard data in healthy Japanese) and background factors such as age, sex, education, smoking status, mini‐mental state examination score, body mass index, systolic blood pressure, severity of depression, alcohol consumption, and laboratory findings were analyzed. Multiple regression analysis showed that the age (p < 0.001) and total bilirubin level (p = 0.014) were worsening factors for the BACS‐J composite raw score, whereas education (p < 0.001) was a protective factor. An inverse correlation was apparent between the age and the composite Z‐score of the BACS‐J (r = −0.431, p < 0.001). Receiver operating characteristic (ROC) analysis identified 53 years as the cutoff age for predicting more than −2SD cognitive decline from the normal standard, with a high negative predictive value (95%). Patients with AUD aged ≥53 years showed more pronounced impairments in verbal memory, working memory, verbal fluency, and attention than those younger than 53 years (p < 0.05). These findings clearly demonstrate accelerated age‐related cognitive decline in patients with AUD, especially those aged ≥53 years, suggesting the necessity of early intervention in patients with AUD to prevent progressive cognitive impairment and preserve their quality of life.
- 5 November 2023
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 43 (4) , 587-595
Open AccessAge‐related cognitive decline is accelerated in alcohol use disorder
This study aimed to examine potential cognitive impairments in patients with alcohol use disorder (AUD), and explore the factors affecting them. We recruited 97 inpatients with AUD, showing superficially normal cognitive function (mini‐mental state examination score ≥24) for this study. We assessed cognitive function after a 4‐week post‐abstinence period using the Brief Assessment of Cognition in Schizophrenia‐Japanese version (BACS‐J). Relationships between BACS‐J subcategory/composite raw scores and Z‐scores (deviation from standard data in healthy Japanese) and background factors such as age, sex, education, smoking status, mini‐mental state examination score, body mass index, systolic blood pressure, severity of depression, alcohol consumption, and laboratory findings were analyzed. Multiple regression analysis showed that the age (p < 0.001) and total bilirubin level (p = 0.014) were worsening factors for the BACS‐J composite raw score, whereas education (p < 0.001) was a protective factor. An inverse correlation was apparent between the age and the composite Z‐score of the BACS‐J (r = −0.431, p < 0.001). Receiver operating characteristic (ROC) analysis identified 53 years as the cutoff age for predicting more than −2SD cognitive decline from the normal standard, with a high negative predictive value (95%). Patients with AUD aged ≥53 years showed more pronounced impairments in verbal memory, working memory, verbal fluency, and attention than those younger than 53 years (p < 0.05). These findings clearly demonstrate accelerated age‐related cognitive decline in patients with AUD, especially those aged ≥53 years, suggesting the necessity of early intervention in patients with AUD to prevent progressive cognitive impairment and preserve their quality of life.